#GLMD

3 months ago

Galmed (NASDAQ: GLMD) links Aramchol to Phase 1/2 HCC combo trial at HEP-DART 2025 Late-breaking HEP-DART 2025 poster details Aramchol plus regorafenib in HCC and GI cancers, supporting a VCU Massey Phase 1/2 trial set to start enrollment in 2026.

#GLMD Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

www.stocktitan.net/news/GLMD/galmed-announc...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH Galmed (NASDAQ: GLMD) announced a new use patent in South Korea covering a combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (resmetirom) for the treatment of non-alcoholic steatohepatitis (NASH/MASH) and liver fibrosis.The company says this grant joins earlier patents in the United States, Europe, Canada and other jurisdictions and extends Aramchol's patent protection worldwide, with U.S. protection noted through July 2042. Galmed describes Aramchol as a Phase 3–ready candidate with reported fibrosis improvement and favorable safety and tolerability, positioning it for combination therapy development in MASH.

#GLMD Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

www.stocktitan.net/news/GLMD/galmed-announc...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

#GLMD Galmed Issues CEO Letter to Shareholders

www.stocktitan.net/news/GLMD/galmed-issues-...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

#GLMD Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/GLMD/galmed-pharmac...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

#GLMD Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

www.stocktitan.net/news/GLMD/galmed-announc...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Instead, a new UK- based company has been established by Allen Baharaff, the Galmed CEO, for the development and commercialization of the SEDDS formulation in which it is contemplated that Galmed will acquire up to 20% of its share capital through an investment of up to $2 million, subject to execution of definitive documentation and approval of Galmed's board...

#GLMD Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/GLMD/galmed-pharmac...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Biotech Firm Galmed Plans 50% Cash-to-Crypto Move: $10M Digital Asset Strategy Marks Major Shift Galmed Pharmaceuticals adopts crypto treasury strategy, investing up to $10M in digital assets. Partners with Tectona for management. Increases authorized shares to 900M from 50M.

#GLMD Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

www.stocktitan.net/news/GLMD/galmed-announc...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Galmed's New Biomarker Discovery Could Transform Drug into Multi-Billion Dollar Heart Disease Treatment Novel 70-protein signature reveals Aramchol's potential beyond liver disease, showing promising heart failure biomarker reduction. See expansion strategy details.

#GLMD Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH

www.stocktitan.net/news/GLMD/galmed-identif...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Galmed Reports Breakthrough: Aramchol Enhances Bayer's Cancer Drug Effect, Adds Novel Semaglutide Program New oncology data reveals Aramchol's potential in GI cancer treatment. Plus, development plans for novel semaglutide formulation. See full financial results.

#GLMD Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/GLMD/galmed-pharmac...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models Galmed Pharmaceuticals (NASDAQ: GLMD) announced significant results for Aramchol, their SCD1 inhibitor drug, in pre-clinical models of primary sclerosing cholangitis (PSC). The study showed Aramchol both prevented and reduced biliary fibrosis in PSC mouse models, with a 2-fold significant inhibition (p of TGFβ-induced hepatic fibrosis pathways. The drug demonstrated dose-dependent reduction in fibrotic markers and hepatic stellate cell-activating genes in human and mouse cells. These findings are particularly significant as PSC carries a 20% lifetime risk of developing cholangiocarcinoma (CCA), the second-most prevalent liver malignancy. Building on previous successful clinical trials showing improvement in liver fibrosis, including the ARREST Phase IIb trial and ARMOR Phase III study, Galmed plans to advance Aramchol towards Phase 2/3 clinical studies focusing on GI oncology indications.

#GLMD Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models

www.stocktitan.net/news/GLMD/galmed-reports...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

10 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Tue May 6th - #TOPP #VSA #TDUP #SLGL #RGC #MRIN #HTRX #GLMD #FARO #EVGO #DHC #AORT #EQV #CCLD #BTMD #IHS #IPI #VCSA #FOXO #ADN - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Groundbreaking Cancer Treatment: How Galmed's Drug Enhances Bayer's Cancer Medicine by Targeting New Pathway Novel drug combination shows enhanced tumor-killing effect in GI cancers. Phase 1b trial planned for Q4 2025 at VCU Massey Cancer Center. See full study results.

#GLMD Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

www.stocktitan.net/news/GLMD/galmed-announc...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Revolutionary Sublingual Semaglutide Could Challenge Ozempic: $120B Market Opportunity Ahead New sublingual formulation aims to outperform Rybelsus with enhanced bioavailability. Targeting early 2026 launch in key markets. Get exclusive development details.

#GLMD Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

www.stocktitan.net/news/GLMD/galmed-signed-...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Galmed Tackles 75% Cancer Treatment Gap: New Research Targets Drug-Resistant GI Cancers Breakthrough collaboration explores Aramchol's potential against resistant GI cancers. VCU research targets 75% of patients unresponsive to current therapies. See study details.

#GLMD Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

www.stocktitan.net/news/GLMD/galmed-pharmac...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Clinical Trial Success: New Drug Formulation Achieves 2X Better Absorption, FDA Backs Development Latest clinical data reveals enhanced drug formulation doubles bioavailability, enables once-daily dosing. FDA approves development pathway under new IND. See full analysis.

#GLMD Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

www.stocktitan.net/news/GLMD/galmed-announc...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Just Released: Galmed Pharmaceuticals Latest Annual Report Reveals Full Financial Picture Access Galmed's comprehensive 2024 Form 20-F annual report covering liver and cardiometabolic drug developments. Full financial details inside.

#GLMD Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

www.stocktitan.net/news/GLMD/galmed-pharmac...

0 0 0 0